Role of Volatile Anesthetics for Hepatic Protection

This study aims to evaluate the attenuation of ischemic-reperfusion injury in the liver after sevoflurane preconditioning. In the presence of sevoflurane, an attenuation of liver injury is hypothesized (diminished increase of liver enzymes, reduced production of inflammatory mediators).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Reperfusion Injury Cardiovascular Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Postoperative Complications Vascular Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital of Zurich

Zurich, Switzerland

About this study

Organ protection; preconditioning; volatile anesthetics; ischemia reperfusion

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Older than 18 years of age
Patients undergoing liver resection (benign or malignant tumors)

Exclusion criteria

Laparoscopic liver resection coagulopathy (platelets < 50,000/ml, Quick < 50%)
Liver cirrhosis

Treatment and study plan

Sevoflurane

Drug

Primary outcomes

Blood levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT)

Sponsors and collaborators

Lead sponsor

University of Zurich

Other

Registry information

Official study title

Role of Volatile Anesthetics for Hepatic Protection in Ischemia-reperfusion

Important dates

Study start: 2006
Primary completion: 2007
Study completion: 2007
First posted: Aug 15, 2007
Registry last updated: Sep 15, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed